{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for angiotensin root_notes_note in Note (approximate match)
Status:
US Previously Marketed
Source:
Hypertensin by Novartis
(1961)
Source URL:
First approved in 1961
Source:
Hypertensin by Novartis
Source URL:
Class:
PROTEIN
Conditions:
Angiotensinamide is octapeptide amide of bovine angiotensin II used to increase blood pressure by vasoconstriction. Angiotensinamide is indicated for the treatment of severe hypotension unresponsive to traditional pressor agents. Angiotensinamide has a strong pressure effect, due to the increased peripheral resistance of blood vessels, especially small caliber arterioles. Under the influence of angiotensinamide, the vessels of the internal organs, skin, kidneys are particularly narrowed. Blood circulation in skeletal muscles and coronary vessels does not change significantly. The drug has no direct effect on the heart and does not cause arrhythmias in therapeutic doses. Angiotensinamide is rapidly inactivated by enzymes contained in the blood, and therefore, when administered once, it has a short-term (2–3 min) pressure effect. However, the duration of the effect can be relatively easily controlled by selecting the appropriate rate of administration of the drug solution.
Status:
Possibly Marketed Outside US
Source:
ANDA075357
(2023)
Source URL:
First approved in 2023
Source:
ANDA075357
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Other
Class:
POLYMER
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Excipient
Source:
26mg ORAL TABLET, FILM COATED, EXTENDED RELEASE
Source URL:
Class:
G1 SPECIFIED SUBSTANCE
Status:
Excipient
Class:
G1 SPECIFIED SUBSTANCE